DOUBLE BOND Pharmaceutical

Uppsala 2017-02-06

Promising results for Temodex, drug candidate against brain cancer, after completion of the first MGMT study

A pilot study has now been completed to determine whether the MGMT status affects the effectiveness of treatment with Temodex. Preliminary findings show no significant difference.

Preliminary results indicate that there is no significant difference in survival between MGMT methylation-positive and negative patients treated with Temodex, and that all patients who received Temodex had a significantly better survival than the control group when both DNA and protein data for MGMT were taken into account. This result will later this year be presented at scientific meetings and in scientific journals. Further studies on a larger group of patients are scheduled to start shortly.

"MGMT status permits to distinguish patients who respond well or respond poorly to standard-of-care chemotherapy with temozolomide. That MGMT status does not seem to be as critical for patient survival after treatment with Temodex in combination with standard treatment can mean that Temodex has a chance to become the most effective chemotherapeutic treatment for patients who respond poorly to standard therapy with temozolomide, "- says Dr. Iulia Karlsson, Head of Biomarker and Companion Diagnostics Development in DBP.

"This study creates a very strong profile for Temodex and gives us great opportunities ahead to continue our development toward making Temodex a new effective drug against brain cancer", - says Igor Lokot, CEO of Double Bond Pharmaceutical.

More about Temodex

Temodex, which is a locally acting formulation of temozolomide, was developed by RI PCP in Minsk, Belarus, and is registered for marketing within Belarus since 2014 as the first-line treatment of glioblastoma. Temodex was acquired by DBP in autumn 2015 and is now being prepared to pass through all the tests and trials required for registration within the EU and globally. Find out more here.

Full Company Name:	Double Bond Pharmaceutical International AB (publ)
Corporate identity:	556991-6082
Stock short name:	DBP B
Share ISIN code:	SE0007185525

For more info, contact
Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com

Blogg: http://blog.doublebp.com

Follow us on LinkedIn and Twitter!

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company's own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. DBP acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015. The company was granted Orphan Drug Designation status by EMA for Temodex in July 2016.